Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Repisalud
Publicación Artículo científico (JournalArticle)

Clinical Outcomes in Duchenne Muscular Dystrophy: A Study of 5345 Patients from the TREAT-NMD DMD Global Database

  • Koeks, Zaïda
  • Bladen, Catherine L
  • Salgado, David
  • van Zwet, Erik
  • Pogoryelova, Oksana
  • McMacken, Grace
  • Monges, Soledad
  • Foncuberta, Maria E
  • Kekou, Kyriaki
  • Kosma, Konstantina
  • Dawkins, Hugh
  • Lamont, Leanne
  • Bellgard, Matthew I
  • Roy, Anna J
  • Chamova, Teodora
  • Guergueltcheva, Velina
  • Chan, Sophelia
  • Korngut, Lawrence
  • Campbell, Craig
  • Dai, Yi
  • Wang, Jen
  • Barišić, Nina
  • Brabec, Petr
  • Lähdetie, Jaana
  • Walter, Maggie C
  • Schreiber-Katz, Olivia
  • Karcagi, Veronika
  • Garami, Marta
  • Herczegfalvi, Agnes
  • Viswanathan, Venkatarman
  • Bayat, Farhad
  • Buccella, Filippo
  • Ferlini, Alessandra
  • Kimura, En
  • van den Bergen, Janneke C
  • Rodrigues, Miriam
  • Roxburgh, Richard
  • Lusakowska, Anna
  • Kostera-Pruszczyk, Anna
  • Santos, Rosário
  • Neagu, Elena
  • Artemieva, Svetlana
  • Rasic, Vedrana Milic
  • Vojinovic, Dina
  • Posada De la Paz, Manuel
  • Bloetzer, Clemens
  • Klein, Andrea
  • Díaz-Manera, Jordi
  • Gallardo, Eduard
  • Karaduman, A Ayşe
  • Oznur, Tunca
  • Topaloğlu, Haluk
  • El Sherif, Rasha
  • Stringer, Angela
  • Shatillo, Andriy V
  • Martin, Ann S
  • Peay, Holly L
  • Kirschner, Jan
  • Flanigan, Kevin M
  • Straub, Volker
  • Bushby, Kate
  • Béroud, Christophe
  • Verschuuren, Jan J
  • Lochmüller, Hanns
Background: Recent short-term clinical trials in patients with Duchenne Muscular Dystrophy (DMD) have indicated greater disease variability in terms of progression than expected. In addition, as average life-expectancy increases, reliable data is required on clinical progression in the older DMD population. Objective: To determine the effects of corticosteroids on major clinical outcomes of DMD in a large multinational cohort of genetically confirmed DMD patients. Methods: In this cross-sectional study we analysed clinical data from 5345 genetically confirmed DMD patients from 31 countries held within the TREAT-NMD global DMD database. For analysis patients were categorised by corticosteroid background and further stratified by age. Results: Loss of ambulation in non-steroid treated patients was 10 years and in corticosteroid treated patients 13 years old (p = 0.0001). Corticosteroid treated patients were less likely to need scoliosis surgery (p < 0.001) or ventilatory support (p < 0.001) and there was a mild cardioprotective effect of corticosteroids in the patient population aged 20 years and older (p = 0.0035). Patients with a single deletion of exon 45 showed an increased survival in contrast to other single exon deletions. Conclusions: This study provides data on clinical outcomes of DMD across many healthcare settings and including a sizeable cohort of older patients. Our data confirm the benefits of corticosteroid treatment on ambulation, need for scoliosis surgery, ventilation and, to a lesser extent, cardiomyopathy. This study underlines the importance of data collection via patient registries and the critical role of multi-centre collaboration in the rare disease field.
Repisalud
Publicación Artículo científico (JournalArticle)

The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations

  • Bladen, Catherine L
  • Salgado, David
  • Monges, Soledad
  • Foncuberta, Maria E
  • Kekou, Kyriaki
  • Kosma, Konstantina
  • Dawkins, Hugh
  • Lamont, Leanne
  • Roy, Anna J
  • Chamova, Teodora
  • Guergueltcheva, Velina
  • Chan, Sophelia
  • Korngut, Lawrence
  • Campbell, Craig
  • Dai, Yi
  • Wang, Jen
  • Barišić, Nina
  • Brabec, Petr
  • Lähdetie, Jaana
  • Walter, Maggie C
  • Schreiber-Katz, Olivia
  • Karcagi, Veronika
  • Garami, Marta
  • Viswanathan, Venkatarman
  • Bayat, Farhad
  • Buccella, Filippo
  • Kimura, En
  • Koeks, Zaïda
  • van den Bergen, Janneke C
  • Rodrigues, Miriam
  • Roxburgh, Richard
  • Lusakowska, Anna
  • Kostera-Pruszczyk, Anna
  • Zimowski, Janusz
  • Santos, Rosário
  • Neagu, Elena
  • Artemieva, Svetlana
  • Rasic, Vedrana Milic
  • Vojinovic, Dina
  • Posada De la Paz, Manuel
  • Bloetzer, Clemens
  • Jeannet, Pierre-Yves
  • Joncourt, Franziska
  • Díaz-Manera, Jordi
  • Gallardo, Eduard
  • Karaduman, A Ayşe
  • Topaloğlu, Haluk
  • El Sherif, Rasha
  • Stringer, Angela
  • Shatillo, Andriy V
  • Martin, Ann S
  • Peay, Holly L
  • Bellgard, Matthew I
  • Kirschner, Jan
  • Flanigan, Kevin M
  • Straub, Volker
  • Bushby, Kate
  • Verschuuren, Jan
  • Aartsma-Rus, Annemieke
  • Béroud, Christophe
  • Lochmüller, Hanns
Analyzing the type and frequency of patient-specific mutations that give rise to Duchenne muscular dystrophy (DMD) is an invaluable tool for diagnostics, basic scientific research, trial planning, and improved clinical care. Locus-specific databases allow for the collection, organization, storage, and analysis of genetic variants of disease. Here, we describe the development and analysis of the TREAT-NMD DMD Global database (http://umd.be/TREAT_DMD/). We analyzed genetic data for 7,149 DMD mutations held within the database. A total of 5,682 large mutations were observed (80% of total mutations), of which 4,894 (86%) were deletions (1 exon or larger) and 784 (14%) were duplications (1 exon or larger). There were 1,445 small mutations (smaller than 1 exon, 20% of all mutations), of which 358 (25%) were small deletions and 132 (9%) small insertions and 199 (14%) affected the splice sites. Point mutations totalled 756 (52% of small mutations) with 726 (50%) nonsense mutations and 30 (2%) missense mutations. Finally, 22 (0.3%) mid-intronic mutations were observed. In addition, mutations were identified within the database that would potentially benefit from novel genetic therapies for DMD including stop codon read-through therapies (10% of total mutations) and exon skipping therapy (80% of deletions and 55% of total mutations).
Repisalud
Publicación Artículo científico (JournalArticle)

The EuroBioBank Network: 10 years of hands-on experience of collaborative, transnational biobanking for rare diseases

  • Mora, Marina
  • Angelini, Corrado
  • Bignami, Fabrizia
  • Bodin, Anne-Mary
  • Crimi, Marco
  • Di Donato, Jeanne-Hélène
  • Felice, Alex
  • Jaeger, Cécile
  • Karcagi, Veronika
  • LeCam, Yann
  • Lynn, Stephen
  • Meznaric, Marija
  • Moggio, Maurizio
  • Monaco, Lucia
  • Politano, Luisa
  • Posada De la Paz, Manuel
  • Saker, Safaa
  • Schneiderat, Peter
  • Ensini, Monica
  • Garavaglia, Barbara
  • Gurwitz, David
  • Johnson, Diana
  • Muntoni, Francesco
  • Puymirat, Jack
  • Reza, Mojgan
  • Voit, Thomas
  • Baldo, Chiara
  • Bricarelli, Franca Dagna
  • Goldwurm, Stefano
  • Merla, Giuseppe
  • Pegoraro, Elena
  • Renieri, Alessandra
  • Zatloukal, Kurt
  • Filocamo, Mirella
  • Lochmüller, Hanns
The EuroBioBank (EBB) network (www.eurobiobank.org) is the first operating network of biobanks in Europe to provide human DNA, cell and tissue samples as a service to the scientific community conducting research on rare diseases (RDs). The EBB was established in 2001 to facilitate access to RD biospecimens and associated data; it obtained funding from the European Commission in 2002 (5th framework programme) and started operation in 2003. The set-up phase, during the EC funding period 2003-2006, established the basis for running the network; the following consolidation phase has seen the growth of the network through the joining of new partners, better network cohesion, improved coordination of activities, and the development of a quality-control system. During this phase the network participated in the EC-funded TREAT-NMD programme and was involved in planning of the European Biobanking and Biomolecular Resources Research Infrastructure. Recently, EBB became a partner of RD-Connect, an FP7 EU programme aimed at linking RD biobanks, registries, and bioinformatics data. Within RD-Connect, EBB contributes expertise, promotes high professional standards, and best practices in RD biobanking, is implementing integration with RD patient registries and 'omics' data, thus challenging the fragmentation of international cooperation on the field.
Repisalud
Publicación Artículo de revisión (ReviewArticle)

Current trends in biobanking for rare diseases: a review

  • Graham, Caroline E
  • Molster, Caron
  • Baynam, Gareth
  • Bushby, Kate
  • Hansson, Mats
  • Kole, Anna
  • Mora, Marina
  • Monaco, Lucia
  • Bellgard, Matthew I
  • Carpentieri, David
  • Posada De la Paz, Manuel
  • Riess, Olaf
  • Rubinstein, Yaffa R
  • Schaefer, Franz
  • Taruscio, Domenica
  • Terry, Sharon F
  • Zatloukal, Kurt
  • Knoppers, Bartha
  • Lochmüller, Hanns
  • Dawkins, Hugh
Rare diseases (RD) refer to a collection of approximately 5,000–8,000 individual diseases that have a low prevalence and are often genetic in origin. While RD can manifest throughout life, they frequently affect children and newborns. Common characteristics include being severe, disabling, life-threatening, degenerative and affecting different organ systems. The burden of RD is often exacerbated by a lack of specific treatments. Whilst there is etiological heterogeneity, there is overlap in cellular and molecular pathways. Amongst specialists, there is legitimate hope that based on genetic knowledge and pathway definition, a new medical classification system, currently called “precision medicine”, will be developed, which may change our view on how to apply shared therapeutic targets. Thus, collection of clinical and genetic data and biospecimens (in biobanks) will play an increasing role in diagnoses and development of therapies for RD. Biobanks are maintained collaboratively by researchers or their institutions, and involve a delicate balance between health policy objectives, academic research, public good outcomes, and community trust. Due to the nature of RD, international cooperation is critical for sharing limited numbers of RD samples and achieving a critical mass. Here we review the current and future direction of RD biobanks and discuss research and development stemming from the use of biospecimens to improve management of RD.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Physical exercise shapes the mouse brain epigenome

  • Urdinguio, Rocío G.
  • Tejedor, Juan Ramón
  • Fernández-Sanjurjo, Manuel
  • Pérez, Raúl F.
  • Peñarroya, Alfonso
  • Ferrero, Cecilia
  • Codina-Martínez, Helena
  • Díez-Planelles, Carlos
  • Pinto-Hernández, Paola
  • Castilla-Silgado, Juan
  • Coto-Vilcapoma, Almudena
  • Díez-Robles, Sergio
  • Blanco-Agudín, Noelia
  • Tomás-Zapico, Cristina
  • Iglesias-Gutiérrez, Eduardo
  • Fernández-García, Benjamín
  • Fernández, Agustín F.
  • Fraga, Mario F.
[Objective]: To analyze the genome-wide epigenomic and transcriptomic changes induced by long term resistance or endurance training in the hippocampus of wild-type mice., [Methods]: We performed whole-genome bisulfite sequencing (WGBS) and RNA sequencing (RNA-seq) of mice hippocampus after 4 weeks of specific training. In addition, we used a novel object recognition test before and after the intervention to determine whether the exercise led to an improvement in cognitive function., [Results]: Although the majority of DNA methylation changes identified in this study were training-model specific, most were associated with hypomethylation and were enriched in similar histone marks, chromatin states, and transcription factor biding sites. It is worth highlighting the significant association found between the loss of DNA methylation in Tet1 binding sites and gene expression changes, indicating the importance of these epigenomic changes in transcriptional regulation. However, endurance and resistance training activate different gene pathways, those being associated with neuroplasticity in the case of endurance exercise, and interferon response pathways in the case of resistance exercise, which also appears to be associated with improved learning and memory functions., [Conclusions]: Our results help both understand the molecular mechanisms by which different exercise models exert beneficial effects for brain health and provide new potential therapeutic targets for future research., This work was supported by the Spanish Association Against Cancer (PROYE18061FERN to M.F.F.), the Asturias Government (PCTI) co-funding 2018-2022/FEDER (IDI/2018/146 to M.F.F.), the Fundación General CSIC (0348_CIE_6_E to M.F.F.), the Health Institute Carlos III (Plan Nacional de I+D+I) co-funding FEDER (PI18/01527 to M.F.F and A.F.F.), the MINECO (DEP2015-69980-P to B.F.G.), and the Fundación Tatiana Pérez de Guzmán el Bueno (“Ayudas a Proyectos de Investigación en Neurociencia-2020” to C.T.Z and E.I.G.). R.G.U. is supported by the Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER). J.R.T. is supported by a Juan de la Cierva fellowship from the Spanish Ministry of Science and Innovation MCIN/AEI /10.13039/501100011033 (IJC2018-036825-I). R.F.P. is supported by the Severo Ochoa program (BP17-114). P.P.H. is supported by Ayudas para la realización de Tesis Doctorales. Modalidad A fellowship from the University of Oviedo (PAPI-20-PF-19). We also acknowledge support from the IUOPA-ISPA-FINBA (the IUOPA is supported by the Obra Social Cajastur-Liberbank, Spain)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Nicotinamide N-methyltransferase (NNMT) regulates the glucocorticoid signaling pathway during the early phase of adipogenesis

  • Roberti, Annalisa
  • Tejedor, Juan Ramón
  • Díaz-Moreno, Irene
  • López, Virginia
  • Santamarina-Ojeda, Pablo
  • Pérez, Raúl F.
  • Urdinguio, Rocío G.
  • Concellón, Carmen
  • Martínez-Chantar, María Luz
  • Fernández-Morera, Juan L.
  • Díaz-Quintana, Antonio
  • Amo, Vicente del
  • Fernández, Agustín F.
  • Fraga, Mario F.
Obesity is associated with adipose tissue dysfunction through the differentiation and expansion of pre-adipocytes to adipocytes (hyperplasia) and/or increases in size of pre-existing adipocytes (hypertrophy). A cascade of transcriptional events coordinates the differentiation of pre-adipocytes into fully differentiated adipocytes; the process of adipogenesis. Although nicotinamide N-methyltransferase (NNMT) has been associated with obesity, how NNMT is regulated during adipogenesis, and the underlying regulatory mechanisms, remain undefined. In present study we used genetic and pharmacological approaches to elucidate the molecular signals driving NNMT activation and its role during adipogenesis. Firstly, we demonstrated that during the early phase of adipocyte differentiation NNMT is transactivated by CCAAT/Enhancer Binding Protein beta (CEBPB) in response to glucocorticoid (GC) induction. We found that Nnmt knockout, using CRISPR/Cas9 approach, impaired terminal adipogenesis by influencing the timing of cellular commitment and cell cycle exit during mitotic clonal expansion, as demonstrated by cell cycle analysis and RNA sequencing experiments. Biochemical and computational methods showed that a novel small molecule, called CC-410, stably binds to and highly specifically inhibits NNMT. CC-410 was, therefore, used to modulate protein activity during pre-adipocyte differentiation stages, demonstrating that, in line with the genetic approach, chemical inhibition of NNMT at the early stages of adipogenesis impairs terminal differentiation by deregulating the GC network. These congruent results conclusively demonstrate that NNMT is a key component of the GC-CEBP axis during the early stages of adipogenesis and could be a potential therapeutic target for both early-onset obesity and glucocorticoid-induced obesity., This work was supported by the Spanish Association Against Cancer (PROYE18061FERN to M.F.F.), the Asturias Government (PCTI) co-funding 2018-2023/FEDER (IDI/2018/146 and IDI/2021/000077 to M.F.F.), the Health Institute Carlos III (Plan Nacional de I+D+I) co-funding FEDER (PI18/01527 and PI21/01067 to M.F.F and A.F.F.), CIBERER Acciones Cooperativas y Complementarias Intramurales (ACCI20-35 to M.F.F.), the Fundación General CSIC (0348_CIE_6_E to M.F.F.), the ISCIII (COV00624 to J.R.T. and M.F.F.), ISPA and the Asociación Galbán (2021-052-INTRAMUR GALBAN-GOURR to R.G.U.), ISPA-Jannsen (2021-048-INTRAMURAL NOV-TEVAR to J.R.T.), CSIC (202020E092 to M.F.F), and the European Commission NextGenerationEU, through CSIC’s Global Health Platform (PTI Salud Global) and the Spanish Ministry of Science and Innovation through the Recovery, Transformation and Resilience Plan (SGL2021-03-39 and SGL2021-03-040). The authors are also grateful to the Spanish Ministry of Science and Innovation (PID2021-126663NB-100; CTQ2016-76829-R; PID2020-113473GB-I00), the Regional Government of Andalusia (BIO198 and P18-FR-3487) and the Ramón Areces Foundation (2021-2024). A.R. is supported by CSIC (SOLAUT_00038505 SGL2103040). J.R.T. is supported by a Juan de la Cierva fellowship from the Spanish Ministry of Science and Innovation MCIN/AEI/https://doi.org/10.13039/501100011033 (IJC2018-036825-I). R.F.P. (BP17-114) and P.S.M. (BP17-165) are supported by the Severo Ochoa program. R.G.U. is supported by the Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER). M.L.M.-C is supported by grants from Ministerio de Ciencia, Innovación y Universidades (MICINN) PID2020-117116RB-I00 integrated in Plan Estatal de Investigación Científica y Técnica y Innovación (to M.L.M.-C), and co-funded with Fondos FEDER (to M.L.M.-C), Subprograma Retos Colaboración RTC2019-007125-1 (to M.L.M.-C), La Caixa Foundation Program HR17-00601 (to MLM-C), Proyectos Investigación en Salud DTS20/00138 (to M.L.M.-C), Departamento de Industria del Gobierno Vasco (to M.L.M.-C), Elkartek (KK-2020/00008) (to M.L.M.-C). We also acknowledge support from the Institute of Oncology of Asturias (IUOPA, supported by Obra Social Cajastur Liberbank, Spain), the Health Research Institute of Asturias (ISPA-FINBA) and Consorcio Centro de Investigación Biomédica en Red (CIBERER-ISCIII)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

CRISPR/dCAS9-mediated DNA demethylation screen identifies functional epigenetic determinants of colorectal cancer

  • Tejedor, Juan Ramón
  • Peñarroya, Alfonso
  • Gancedo-Verdejo, Javier
  • Santamarina-Ojeda, Pablo
  • Pérez, Raúl F.
  • López-Tamargo, Sara
  • Díez-Borge, Ana
  • Alba-Linares, Juan J.
  • González-Del-Rey, Nerea
  • Urdinguio, Rocío G.
  • Mangas, Cristina
  • Roberti, Annalisa
  • López, Virginia
  • Morales-Ruiz, Teresa
  • Ariza, Rafael R.
  • Roldán-Arjona, Teresa
  • Meijón, Mónica
  • Valledor, Luis
  • Cañal, María Jesús
  • Fernández-Martínez, Daniel
  • Fernández-Hevia, María
  • Jiménez-Fonseca, Paula
  • García-Flórez, Luis J.
  • Fernández, Agustín F.
  • Fraga, Mario F.
[Background]: Promoter hypermethylation of tumour suppressor genes is frequently observed during the malignant transformation of colorectal cancer (CRC). However, whether this epigenetic mechanism is functional in cancer or is a mere consequence of the carcinogenic process remains to be elucidated., [Results]: In this work, we performed an integrative multi-omic approach to identify gene candidates with strong correlations between DNA methylation and gene expression in human CRC samples and a set of 8 colon cancer cell lines. As a proof of concept, we combined recent CRISPR-Cas9 epigenome editing tools (dCas9-TET1, dCas9-TET-IM) with a customized arrayed gRNA library to modulate the DNA methylation status of 56 promoters previously linked with strong epigenetic repression in CRC, and we monitored the potential functional consequences of this DNA methylation loss by means of a high-content cell proliferation screen. Overall, the epigenetic modulation of most of these DNA methylated regions had a mild impact on the reactivation of gene expression and on the viability of cancer cells. Interestingly, we found that epigenetic reactivation of RSPO2 in the tumour context was associated with a significant impairment in cell proliferation in p53-/- cancer cell lines, and further validation with human samples demonstrated that the epigenetic silencing of RSPO2 is a mid-late event in the adenoma to carcinoma sequence., [Conclusions]: These results highlight the potential role of DNA methylation as a driver mechanism of CRC and paves the way for the identification of novel therapeutic windows based on the epigenetic reactivation of certain tumour suppressor genes., This work was supported by Health Institute Carlos III (Plan Nacional de I + D + I) co-funding FEDER (PI18/01527 and PI21/01067 to M.F.F. and A.F.F.; COV00624 to J.R.T. and M.F.F.), the Spanish Association Against Cancer (PROYE18061FERN to M.F.F.), the Asturias Government (PCTI) co-funding 2018-2023/FEDER (IDI/2018/146 and IDI/2021/000077 to M.F.F.), The Junta de Andalucía co-funding FEDER (PY20_00051 to T.R.-A.), ISPA-Jannsen (2021-048-INTRAMURAL NOV-TEVAR to J.R.T.) and the European Commission NextGenerationEU, through CSIC’s Global Health Platform (PTI Salud Global) and the Spanish Ministry of Science and Innovation through the Recovery, Transformation and Resilience Plan (SGL2021-03-39 and SGL2021-03-040). J.R.T. is supported by the Spanish Ministry of Science and Innovation (IJC2018-036825-I and RYC2021-031799-I). A.P. is supported by the ISCIII (FI19/00085). J.G.V. is supported by the Spanish Ministry of Universities (FPU20/04659). R.F.P. (BP17-114) and P.S.M. (BP17-165) are supported by the Severo Ochoa program. R.G.U. is supported by the Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER). J.J.A.L. is supported by the AECC fellowship (PRDAS21642ALBA). A.R. is supported by CSIC (SOLAUT_00038505 SGL2103040)., Peer reviewed